Company intelligence / Profile preview
Veana Therapeutics
Oregon, United Statesveana-therapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Veana Therapeutics has developed oral small molecule drugs that selectively target and destroy the mitochondria of cancer cells. This process induces apoptosis and autophagy, leading to enhanced anti-tumor immune responses. The company’s approach aims to both directly kill tumor cells and stimulate the patient’s immune system against cancer.
No specific clinical trial results or phases are publicly disclosed in the provided sources.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules (oral medicines targeting mitochondria)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Veana Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Veana Therapeutics.